1 |
NCT03690921 |
Recruiting |
LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer |
- Anal Canal Squamous Cell Carcinoma
- Stage I Anal Cancer AJCC v8
- Stage II Anal Cancer AJCC v8
- (and 6 more...)
|
- Drug: Cisplatin
- Drug: Fluorouracil
- Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- (and 2 more...)
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Physician-reported acute grade 3 or greater gastrointestinal, genitourinary and hematologic toxicities graded according to Common Terminology Criteria for Adverse Events version 4.0
- Feasibility as determined by number of patients enrolled
- Guidelines and workflow development to create and deliver anal canal cancer treatments using linear energy transfer (LET)-optimized IMPT
- (and 8 more...)
|
48 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03690921 |
2018-0420 NCI-2018-02040 P30CA016672 |
|
November 8, 2018 |
May 23, 2022 |
May 23, 2022 |
October 1, 2018 |
December 19, 2018 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
2 |
NCT03489707 |
Not yet recruiting |
Annual Anal Sampling Using DNA Screening to Identify Men Who Have Sex With Men at Increased Risk for Anal Cancer |
|
- Behavioral: Home-based human papillomavirus (HPV) DNA screening
- Behavioral: Clinic-based human papillomavirus (HPV) DNA screening
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
- Baylor College of Medicine
- National Cancer Institute (NCI)
- The University of Texas Health Science Center, Houston
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Compliance as assessed by the number of participants who provide specimens for annual anal HPV DNA screening
- Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire (pre-test)
- Factors associated with annual screening compliance as assessed by the Computer-Assisted Self-Interview (CASI) questionnaire
- Number of participants who agree to have a high resolution anoscopy (HRA)
|
400 |
Male |
25 Years and older (Adult, Older Adult) |
NCT03489707 |
HSC-MS-17-0635 R01CA215403 |
|
March 15, 2019 |
September 1, 2022 |
September 1, 2022 |
April 5, 2018 |
January 23, 2019 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
3 |
NCT03439085 |
Recruiting |
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated Cancers |
- Human Papillomavirus-16 Positive
- Human Papillomavirus-18 Positive
- Metastatic Malignant Neoplasm
- (and 18 more...)
|
- Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
- Biological: Durvalumab
|
Interventional
|
Phase 2 |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR) evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- ORR evaluated by RECIST version 1.1 and immune related RECIST
- Disease control rate evaluated by RECIST version 1.1
- (and 2 more...)
|
77 |
All |
18 Years and older (Adult, Older Adult) |
NCT03439085 |
2017-0302 NCI-2018-00914 P30CA016672 |
|
November 14, 2018 |
January 31, 2020 |
January 31, 2020 |
February 20, 2018 |
December 25, 2018 |
|
- M D Anderson Cancer Center
Houston, Texas, United States
|
|
4 |
NCT03427411 |
Recruiting |
M7824 in Subjects With HPV Associated Malignancies |
- Human Papilloma Virus
- Cervical Cancer
- Oropharyngeal Cancer
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR)
- duration of response
- overall survival (OS)
- (and 4 more...)
|
120 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03427411 |
180056 18-C-0056 |
|
February 27, 2018 |
December 31, 2020 |
December 31, 2021 |
February 9, 2018 |
January 9, 2019 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
|
5 |
NCT03386500 |
Recruiting |
Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer |
- Anal Cancer, Squamous Cell Carcinoma
- Radiation Exposure
|
|
Interventional
|
Phase 1 |
- Chi Lin, MD
- BioMimetix JV, LLC
- University of Nebraska
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of BMX-001
- Impact of study treatment on acute rectal bleeding
- Impact of study treatment on acute rectal pain
- (and 10 more...)
|
24 |
All |
19 Years and older (Adult, Older Adult) |
NCT03386500 |
247-17 |
|
November 28, 2017 |
December 2019 |
December 2020 |
December 29, 2017 |
December 29, 2017 |
|
- University of Nebraska Medical Center
Omaha, Nebraska, United States
|
|
6 |
NCT03302858 |
Recruiting |
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand |
- HSIL, High Grade Squamous Intraepithelial Lesions
- Anal Cancer
- HPV-Related Squamous Cell Carcinoma
- (and 3 more...)
|
- Device: BARRX™ Anorectal Wand
|
Interventional
|
Phase 2 |
- Stephen E. Goldstone
- Laser Surgery Care
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent of patients who have histologically cleared high-grade squamous intraepithelial lesions (HSIL) at the SCJ at 12 months as measured by HRA
- Persistence of treated HSIL index lesions
- Safety of circumferential ablation of anal canal HSIL using the Barrx™ Anorectal Wand as defined by number of patients with adverse events (including prolonged pain, bleeding, anal strictures, etc).
- Percent of patients who have histologically cleared low-grade squamous intraepithelial lesions (LSIL) at the SCJ at 12 months as measured by HRA
|
70 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03302858 |
01-2017 |
|
October 2017 |
October 2019 |
October 2020 |
October 5, 2017 |
October 5, 2017 |
|
- Laser Surgery Care
New York, New York, United States
|
|
7 |
NCT03018418 |
Recruiting |
Proton Therapy in Reducing Toxicity in Anal Cancer |
|
- Radiation: Proton therapy
- Drug: Chemotherapy
|
Interventional
|
Phase 2 |
- Jordan Kharofa
- University of Cincinnati
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rates of acute toxicity
- Rates of late toxicity
- Complete response rate
- (and 4 more...)
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03018418 |
UCCI-GI-16-01 |
|
January 2017 |
June 2022 |
January 2023 |
January 12, 2017 |
July 28, 2017 |
|
- UC Health
Cincinnati, Ohio, United States
|
|
8 |
NCT02865135 |
Recruiting |
Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer |
- Cancer of Head and Neck
- Cancer of Cervix
- Cancer of Anus
|
|
Interventional
|
Phase 1 Phase 2 |
- Dana-Farber Cancer Institute
- Stand Up To Cancer
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants Experiencing Adverse Events Related to Treatment
- Overall Response Rate
- Overall Survival Rate
- Progression Free Survival Rate
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT02865135 |
15-578 |
|
December 2016 |
May 2019 |
May 2023 |
August 12, 2016 |
September 17, 2018 |
|
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
|
9 |
NCT02698293 |
Recruiting |
A Phase I Study of Photodynamic Therapy (PDT) for High-grade Anal Dysplasia and Microinvasive Anal Cancer |
|
|
Interventional
|
Phase 1 |
- Abramson Cancer Center of the University of Pennsylvania
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT02698293 |
UPCC 08216 |
|
May 16, 2018 |
April 2019 |
April 2021 |
March 3, 2016 |
May 18, 2018 |
|
- Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
|
10 |
NCT02379520 |
Recruiting |
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA |
- Human Papillomavirus-Related Carcinoma
- Human Papillomavirus Positive Oropharyngeal Carcinoma
- Human Papillomavirus Positive Cervical Carcinoma
- (and 3 more...)
|
- Genetic: HPV Specific T Cells
- Drug: Cytoxan
- Drug: Fludarabine
- Biological: Nivolumab
|
Interventional
|
Phase 1 |
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- The Methodist Hospital System
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with dose limiting toxicity (DLT)
- Overall response rate
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT02379520 |
H-36021 HESTIA |
HESTIA |
September 2015 |
October 2019 |
October 2033 |
March 5, 2015 |
December 13, 2018 |
|
- Houston Methodist Hospital
Houston, Texas, United States
|
|
11 |
NCT01416714 |
Recruiting |
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy |
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Collect and store blood samples
- create a database for the collected tissue
- To create tissue microarrays for each gastrointestinal cancer subtype
|
1000 |
All |
Child, Adult, Older Adult |
NCT01416714 |
16294A |
|
July 2, 2008 |
January 2025 |
January 2025 |
August 15, 2011 |
February 7, 2018 |
|
- The University of Chicago
Chicago, Illinois, United States
|
|
12 |
NCT02140021 |
Recruiting |
Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer |
- Cervical Adenocarcinoma
- Cervical Adenocarcinoma In Situ
- Cervical Intraepithelial Neoplasia
- (and 52 more...)
|
- Procedure: Biospecimen Collection
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Not Applicable |
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Prevalence of invasive squamous cell carcinoma of the anus
- Sensitivity and specificity of anal pap testing to diagnose anal dysplasia
- Sensitivity and specificity of anal human papillomavirus (HPV) testing to diagnose anal dysplasia
- Sensitivity and specificity of the combination of anal pap testing + anal HPV testing to diagnose anal dysplasia
|
500 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02140021 |
2014-0021 NCI-2018-02553 P30CA016672 |
|
October 27, 2014 |
October 31, 2020 |
October 31, 2020 |
May 16, 2014 |
November 30, 2018 |
|
- Lyndon Baines Johnson General Hospital
Houston, Texas, United States - M D Anderson Cancer Center
Houston, Texas, United States
|
|
13 |
NCT03677960 |
Recruiting |
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection |
- HSIL, High-Grade Squamous Intraepithelial Lesions
- Human Papilloma Virus Infection
- HIV Infection
- (and 2 more...)
|
- Drug: Topical ABI-1968 cream
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL
- Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.
|
18 |
All |
27 Years and older (Adult, Older Adult) |
NCT03677960 |
ABI-1968-202 |
|
December 17, 2018 |
June 30, 2019 |
June 30, 2019 |
September 19, 2018 |
January 3, 2019 |
|
- Research Center
Chicago, Illinois, United States - Research Center
Darlinghurst, Sydney, Australia
|
|
14 |
NCT02816879 |
Recruiting |
Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men |
- Anal Carcinoma
- HIV Infection
- Human Papillomavirus Infection
|
- Procedure: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Not Applicable |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Accuracy of cytology specimens for Dacron swab compared to flocked nylon (NF) swab in predicting histology outcome
- Ability of APTIMA-HPV to predict risk for HG-AIN
- Ability of Hybrid-capture 2 to predict risk for HG-AIN
- Cost effectiveness analysis evaluating differences in survival, the cost of out-patient procedures & in-patient hospitalizations for invasive anal cancer.
|
375 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02816879 |
RCA169508A NCI-2014-01292 JCCCID370 P30CA016042 R01CA169508 13-000997 |
|
July 9, 2013 |
July 31, 2018 |
July 31, 2019 |
June 29, 2016 |
September 13, 2017 |
|
- Los Angeles Gay and Lesbian Center
Los Angeles, California, United States - UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Desert AIDS Project
Palm Springs, California, United States
|
|
15 |
NCT03499795 |
Recruiting |
VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2 |
|
- Biological: VGX-3100
- Device: CELLECTRA™ 5PSP
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with No Histologic Evidence of Anal or Anal/Peri-Anal HSIL and No Evidence of HPV-16/18 at Week 36
- Number of Local and Systemic Safety Events During 7 Days Following Each Dose
- Number of Adverse Events
- (and 11 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03499795 |
HPV-203 |
|
May 3, 2018 |
August 2020 |
August 2020 |
April 17, 2018 |
January 14, 2019 |
|
- Howard Brown Health (HBH)-Sheridan
Chicago, Illinois, United States - Laser Surgery Care
New York, New York, United States - Clinique de Recherche en Sante
Québec, Quebec, Canada
|
|
16 |
NCT03133286 |
Recruiting |
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) |
- Radiation Therapy
- Cancer
- Cancer of Anus
- (and 16 more...)
|
|
Observational
|
|
- DxTerity Diagnostics
- National Cancer Institute (NCI)
|
Industry / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Obtain pre- and post-irradiation participant-collect blood samples
|
500 |
All |
18 Years and older (Adult, Older Adult) |
NCT03133286 |
DXT-RADTOX-AC03 HHSN261201600051C |
RADIANT |
April 6, 2017 |
September 6, 2019 |
September 6, 2019 |
April 28, 2017 |
February 8, 2019 |
|
- DxTerity Diagnostics
Compton, California, United States - 21st Century Oncology
Bradenton, Florida, United States - 21st Century Oncology
Fort Myers, Florida, United States - 21st Century Oncology
Plantation, Florida, United States
|
|
17 |
NCT02919969 |
Recruiting |
Pembrolizumab in Refractory Metastatic Anal Cancer |
|
|
Interventional
|
Phase 2 |
- Dana-Farber Cancer Institute
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- PD-L1 Positive Response Rate
- Overall Survival
- (and 2 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT02919969 |
16-301 |
|
September 2016 |
March 2020 |
March 2024 |
September 30, 2016 |
November 8, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - Seattle Cancer Care Alliance
Seattle, Washington, United States
|
|
18 |
NCT02437851 |
Recruiting |
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection |
- Anal Squamous Cell Carcinoma
- HIV Infection
- Stage 0 Anal Canal Cancer
- Stage I Anal Canal Cancer
|
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Phase 2 |
- AIDS Malignancy Consortium
- National Cancer Institute (NCI)
- The EMMES Corporation
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of participants with treatment failure at 2 years will be estimated with the binomial proportion and exact one-sided 95% confidence intervals.
- The proportion of participants with incident SISCCA or anal squamous cancers at sites other than the index SISCCA will be estimated using the binomial proportion and its two-sided exact 95% confidence interval.
- The cumulative proportion of study participants who have experienced treatment failure by 3 years will be estimated using the product-limit estimate and its 95% confidence interval using Greenwood's formula.
- The rate of treatment related adverse events including non-healing ulcer, fissure, persistent pain and bleeding, stricture, incontinence, and colostomy 6 months after excision of SISCCA.
|
56 |
All |
Child, Adult, Older Adult |
NCT02437851 |
AMC-092 NCI-2014-02056 U01CA121947 |
|
April 2015 |
July 2019 |
July 2020 |
May 8, 2015 |
May 9, 2018 |
|
- University of California, San Francisco
San Francisco, California, United States - Boston Medical Center
Boston, Massachusetts, United States - Laser Surgery Care
New York, New York, United States - Virginia Mason Medical Center
Seattle, Washington, United States
|
|
19 |
NCT02199236 |
Recruiting |
Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management |
|
- Radiation: endorectal brachytherapy
- Drug: concurrent capecitabine or 5-FU
- Behavioral: Questionnaires
|
Interventional
|
Phase 1 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dose (MTD)
- tumor response
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT02199236 |
14-104 |
|
July 2014 |
July 2019 |
July 2019 |
July 24, 2014 |
July 3, 2018 |
|
- Memorial Sloan Kettering Cancer Center at Basking Ridge
Basking Ridge, New Jersey, United States - Memoral Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - (and 3 more...)
|
|
20 |
NCT03233711 |
Recruiting |
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer |
- Anal Basaloid Carcinoma
- Anal Canal Cloacogenic Carcinoma
- Anal Margin Squamous Cell Carcinoma
- (and 5 more...)
|
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
|
NIH / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival
- Objective response rate
- Severe toxicity interval
- (and 3 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03233711 |
NCI-2017-01347 EA2165 U10CA180820 |
|
April 13, 2018 |
December 30, 2019 |
December 30, 2019 |
July 31, 2017 |
February 22, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 602 more...)
|
|
21 |
NCT02408861 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
- Advanced Malignant Solid Neoplasm
- Anal Carcinoma
- HIV Infection
- (and 6 more...)
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose of nivolumab defined as the starting dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT
- Objective response rate
- Immune function
- (and 2 more...)
|
84 |
All |
19 Years and older (Adult, Older Adult) |
NCT02408861 |
NCI-2015-00461 AMC-095 PAMC-095_R03PAPP01 U01CA121947 UM1CA121947 |
|
August 27, 2015 |
December 31, 2020 |
|
April 6, 2015 |
February 15, 2019 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - UCLA Center for Clinical AIDS Research and Education
Los Angeles, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 27 more...)
|
|
22 |
NCT02314169 |
Recruiting |
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer |
- Anal Canal Squamous Cell Carcinoma
- Metastatic Anal Canal Carcinoma
- Stage IV Anal Canal Cancer AJCC v6 and v7
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate: number of participants with response (Part A)
- Progression-free survival (PFS) (Part B)
- Number of participants with toxicities graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Part A)
- (and 4 more...)
|
137 |
All |
18 Years and older (Adult, Older Adult) |
NCT02314169 |
NCI-2014-02420 NCI9673 P9673_R03PAPPHOLD01 9673 N01CM00032 N01CM00038 N01CM00039 N01CM00071 N01CM00099 N01CM00100 P30CA016672 U10CA180821 UM1CA186704 UM1CA186712 UM1CA186716 |
|
May 1, 2015 |
January 31, 2020 |
|
December 11, 2014 |
February 15, 2019 |
|
- Los Angeles County-USC Medical Center
Los Angeles, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - (and 39 more...)
|
|
23 |
NCT02135419 |
Recruiting |
Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions |
- Anal Cancer
- High-grade Squamous Intraepithelial Lesion
- HIV Infection
- Human Papilloma Virus Infection
|
- Drug: imiquimod
- Drug: fluorouracil
- Device: infrared photocoagulation therapy
- (and 4 more...)
|
Interventional
|
Phase 3 |
- AIDS Malignancy Consortium
- National Cancer Institute (NCI)
- The EMMES Corporation
- (and 2 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Time to anal cancer
- Incidence of adverse events for each treatment
- Quality of life assessed using the Functional Assessment of Incontinence Therapy - Fecal (FAIT-F) questionnaire
|
5058 |
All |
35 Years and older (Adult, Older Adult) |
NCT02135419 |
AMC-A01 NCI-2014-00636 U01CA121947 |
ANCHOR |
September 24, 2014 |
June 30, 2022 |
June 30, 2022 |
May 12, 2014 |
June 1, 2018 |
|
- UCLA CARE Clinic
Los Angeles, California, United States - UCLA School of Nursing
Los Angeles, California, United States - University of California at San Francisco Anal Dysplasia Clinic
San Francisco, California, United States - (and 18 more...)
|
|
24 |
NCT02012699 |
Recruiting |
Integrated Cancer Repository for Cancer Research |
- Pancreatic Cancer
- Thyroid Cancer
- Lung Cancer
- (and 44 more...)
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Development and implementation of a web-based Cancer Collaborative Registry at the University of Nebraska Medical Center (UNMC)/Nebraska Medical Center (NMC)
- Procurement and banking of excess biological material for future analysis
|
9999 |
All |
19 Years to 110 Years (Adult, Older Adult) |
NCT02012699 |
253-13 |
iCaRe2 |
November 2013 |
December 2099 |
December 2099 |
December 16, 2013 |
November 5, 2018 |
|
- University of Alabama Birmingham
Birmingham, Alabama, United States - Penrose Cancer Center
Colorado Springs, Colorado, United States - Halifax Health Medical Center d/b/a Halifax Health
Daytona Beach, Florida, United States - (and 67 more...)
|
|
25 |
NCT01567722 |
Recruiting |
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies |
- Anal Cancer
- Cervical Cancer
- Lung Cancer
- Lymphoma
|
- Genetic: DNA analysis
- Genetic: RNA analysis
- Genetic: gene expression analysis
- (and 5 more...)
|
Observational
|
|
- AIDS Malignancy Consortium
- National Cancer Institute (NCI)
- The EMMES Corporation
- (and 2 more...)
|
Other / NIH / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mutational spectrum of each type of HIV-1 associated malignancy
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT01567722 |
AMC-083 CDR0000729843 U01CA121947 |
|
July 2012 |
June 2020 |
June 2020 |
March 30, 2012 |
January 24, 2019 |
|
- Moores UCSD Cancer Center
La Jolla, California, United States - UCLA Clinical AIDS Research and Education (CARE) Center
Los Angeles, California, United States - University of Miami
Miami, Florida, United States - (and 11 more...)
|
|